Mihael H. Polymeropoulos - 30 Nov 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
President and CEO, Director
Signature
/s/ Mihael Polymeropoulos
Issuer symbol
VNDA
Transactions as of
30 Nov 2021
Net transactions value
-$831,623
Form type
4
Filing time
02 Dec 2021, 15:31:39 UTC
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $382,221 +78,324 +6.4% $4.88 1,299,386 30 Nov 2021 Direct
transaction VNDA Common Stock Sale $824,275 -50,000 -3.8% $16.49 1,249,386 30 Nov 2021 Direct F1, F2
transaction VNDA Common Stock Options Exercise $349,779 +71,676 +5.7% $4.88 1,321,062 01 Dec 2021 Direct
transaction VNDA Common Stock Sale $739,348 -46,200 -3.5% $16.00 1,274,862 01 Dec 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -78,324 -52% $0.000000 71,676 30 Nov 2021 Common Stock 78,324 $4.88 Direct F4
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -71,676 -100% $0.000000* 0 01 Dec 2021 Common Stock 71,676 $4.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 5, 2021 as reflected in this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $16.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The option vested in 48 equal monthly installments beginning on January 6, 2012.